Aspira Women S Health Inc's Competitiveness
A competitive positioning analysis and financial ratio benchmarking of Aspira Women S Health Inc (AWHL) against its publicly traded competitors: sales growth, net income, profitability, valuation and market share, plus each peer's market capitalization, revenue, income and employees. Free below: the top 5 peers. Subscriber access adds the full competitor list and CSV downloads.
Key Findings: Aspira Women S Health Inc vs Its Competitors
- TTM: Trailing 12-month revenue of 9M vs 1,277,415M combined for its competitors (0.0% combined share).
- Trending: Latest-quarter revenue run-rate is decelerating (-99.2% annualized vs trailing 12 months), vs accelerating (+3.1%) for its tracked peer group.
- Growth: Aspira Women S Health Inc generated -99.0% revenue growth year over year in Q2 2026, vs 5.0% for its competitors combined.
- Profitability: Its -14,235.3% net margin compares with 15.1% for the peer group.
- Scale: Aspira Women S Health Inc ranks #13 of 19 companies by market capitalization in the In Vitro & In Vivo Diagnostic Substances industry, holding 0.0% of industry market cap.
- Peer revenue share: Aspira Women S Health Inc accounted for 0.0% of combined revenue among its tracked peer group, up from 0.0% a year earlier.
- Peer differentiation: Revenue per employee of $0.24M compares with $1.26M for the peer group (0.2x).
Every figure above is sourced and cited in detail further down this page (Market Structure, Profitability & Cost Structure, Productivity vs Peers).
AWHL Sales vs. its Competitors, Q2 2026
Aspira Women S Health Inc reported revenue contraction of 99.04 % year on year in Q2 2026, below its competitors' combined revenue growth of 5.03 %.
With a net margin of -14,235.29 %, Aspira Women S Health Inc reported lower profitability than its competitors (15.06 %).
Aspira Women S Health Inc generated 0.00 % of the combined sales of its peer group, up from 0.00 % a year earlier.
API endpoints for this dataset
Aspira Women S Health Inc vs. its Competitors, Q2 2026
Revenue growth, year on year
Net margin
Revenue run-rate vs trailing 12 months
TTM net margin
TTM = trailing twelve months. Run-rate annualizes the latest quarter (×4) and compares it to TTM. In millions of $. High-Confidence Competitors are named as a competitor directly in Aspira Women S Health Inc reports; Similar-Size Competitors are the closest peers by market-cap rank within the same industry; Similar Growth & Profitability Competitors are the closest peers by combined revenue growth, operating margin and ROIC, all independent of the competitor list.
TTM revenue, latest-quarter run-rate and net income/margin benchmarked across Aspira Women S Health Inc and its 4 competitor groupings. Available under Commercial License.
| Entity | TTM Revenue | Rev Run-rate vs TTM |
|---|---|---|
| Aspira Women s Health inc | $12,345M | +12.3% · Accelerating |
| Competitors combined | $12,345M | +12.3% · Accelerating |
| High-Confidence Competitors (4) | $12,345M | +12.3% · Accelerating |
| Similar-Size Competitors (9) | $12,345M | +12.3% · Accelerating |
TTM revenue, run-rate and net margin benchmarking across Aspira Women S Health Inc's competitor groups requires a Commercial License.
For context: the In Vitro & In Vivo Diagnostic Substances industry grew revenue 3.0% year over year, combined, vs -99.0% for Aspira Women S Health Inc. Aspira Women S Health Inc's share of combined industry revenue moved from 0.05% to 0.00%, a loss of 0.05 percentage points.
Aspira Women S Health Inc's Competitor Quality Breadth
Group definitions: see Methodology: Performance Group Definitions.
| Entity | Profitable | Expanding | Above Industry Growth | Distressed |
|---|---|---|---|---|
| Aspira Women s Health inc | - | Yes | Yes | Yes |
| Competitors combined (60) | ||||
| High-Confidence Competitors (7) | ||||
| Similar-Size Competitors (10) |
Source: CSIMarket API, trailing 12 months. Altman Z-Score is not shown here: it is not populated in the underlying data for any company. Percentages are of companies in each group that report the relevant metric, not of the full group size.
AWHL Stock Performance relative to its Competitors
AWHL Stock Performance relative to High-Confidence Competitors
AWHL Stock Performance relative to Similar-Size Competitors
5 Best-Performing Tracked Competitors, Trailing 12 Months
| # | Competitor | TTM Share Price Return | vs U.S.A. 500 |
|---|---|---|---|
| 1 | Natera Inc | 282.9% | Outperformed |
| 2 | Neogenomics Inc | 282.9% | Outperformed |
| 3 | United Fire Group Inc | 282.9% | Outperformed |
| 4 | Guardant Health Inc | 282.9% | Outperformed |
| 5 | Universal Insurance Holdings Inc | 282.9% | Outperformed |
TTM share price return and U.S.A. 500 outperformance for Aspira Women S Health Inc's best-performing competitors requires a Commercial License.
Source: CSIMarket API, trailing 12 months.
Aspira Women S Health Inc's Comment on Competition and Industry Peers
Publicly Traded Peers of Aspira Women s Health inc
Revenue and income for trailing 12 months, in millions of $, except employees| Company | Market Cap | Revenues |
|---|---|---|
 Aspira Women s Health inc |
6.90 | 9.03 |
 Progressive Corp |
135,757.40 | 91,735.00 |
 Marsh and Mclennan Companies Inc |
100,316.97 | 28,470.00 |
 Travelers Companies inc |
84,848.63 | 48,921.00 |
 The Cigna Group |
79,579.26 | 282,382.00 |
 Aon Plc |
73,357.20 | 17,707.00 |
| SUBTOTAL | 1,112,836.31 | 1,312,590.87 |
Sign in to see all competitors of Aspira Women s Health inc .
Sources: see Methodology: Peer & Competitor Identification, Sourcing.
Updated on:
Focus of this report: publicly traded companies. Ten additional tables on Aspira Women s Health inc versus competitors, including market share analysis, are in the navigation menu under Competition. To download the tables, please subscribe.
Aspira Women S Health Inc's Competitors Named by the Company
Competitive relationships identified from Aspira Women S Health Inc reports and corroborating sources, each with a basis and confidence.| Competitor | Basis | Confidence |
|---|---|---|
| AOA Dx | Company report | 85% |
| DotLab | Company report | 85% |
| HERA Biotech | Company report | 85% |
| Proteomics International | Company report | 85% |
| Cleo Diagnostics | Company report | 85% |
| Fujirebio Diagnostics | Company report | 85% |
| Afynia | Company report | 85% |
| Endodiag | Company report | 85% |
| Heranova | Company report | 85% |
| Ziwig | Company report | 85% |
| Grail | Company report | 85% |
| Mercy BioAnalytics | Company report | 85% |
| ClearNote Health | Company report | 85% |
| Exact Sciences | Company report | 85% |
| Abbott Laboratories | Company report | 85% |
| Anixa | Company report | 85% |
| InterVenn Biosciences | Company report | 85% |
| Becton Dickinson | Company report | 85% |
| Angle | Company report | 85% |
| AOA | Company report | 85% |
| Dot.Labs | Company report | 85% |
| InterVenn | Company report | 85% |
| Nic Inc | Company report | 85% |
Company report basis, confidence, active dates and source counts for Aspira Women S Health Inc's named competitors require a Commercial License.
Methodology: see Methodology: Peer & Competitor Identification, Sourcing.
Aspira Women S Health Inc's Business Segment Mix vs Peers
Revenue by operating segment or division, as named and reported by each company. Segment names are the filer's own and are not standardized across companies. Do not assume a same-named or similarly-named segment is defined identically between two companies. Shares are of each company's own total revenue and are not required to sum to 100% (intersegment revenue, unallocated items).| Company | Largest Segment |
|---|---|
| Marsh and Mclennan Companies Inc | Risk 55.31 % |
| Travelers Companies inc | Business Insurance 47.23 % |
| The Cigna Group | Evernorth 86.55 % |
| Aon Plc | Risk Capital 65.40 % |
| Allstate Corp | Allstate Protection 86.96 % |
Source: operating segment revenue as reported in each company's reports (10-K/10-Q), via the CSIMarket API, leaf-level reportable segments only (parent roll-up segments are excluded where sub-segments are separately disclosed).
Sign in to see all peers for Aspira Women s Health inc .
Aspira Women S Health Inc's Productivity vs Peers Comparison
Revenue and income per employee, trailing 12 months, in $; market cap in millions of $| Company | Market Cap | Revenue / Employee | Income / Employee |
|---|---|---|---|
| Aspira Women s Health inc | 7 | 237,605 | -263,289 |
| Progressive Corp | 135,757 | 1,834,700 | 232,440 |
| Marsh and Mclennan Companies Inc | 100,317 | 299,684 | 43,358 |
| Travelers Companies inc | 84,849 | 1,438,853 | 244,618 |
| The Cigna Group | 79,579 | 4,171,078 | 102,555 |
| Aon Plc | 73,357 | 295,117 | 65,750 |
| PEERS TOTAL | 1,112,829 | 1,262,902 | 172,220 |
Sign in to see all peers for Aspira Women s Health inc .
Aspira Women S Health Inc's Geographic Revenue Exposure vs Peers
Revenue by country/region as reported in each company's most recent report. Disclosure granularity varies by filer (some report by country, others by broad region) and is shown as disclosed.| Company | Largest Market |
|---|---|
| Aon Plc | Europe, Middle East, and Africa, Other Than United Kingdom and Ireland 14.78 % |
| Natera Inc | United States 98.02 % |
| Brown and Brown Inc | US 88.00 % |
| Guardant Health Inc | United States 95.67 % |
| Ncr Atleos Corporation | United States 46.86 % |
Source: revenue geography as reported in each company's reports (10-K/10-Q), via the CSIMarket API. Percentages are of that company's own total consolidated revenue for its most recent reported period.
Sign in to see all peers for Aspira Women s Health inc .
Aspira Women S Health Inc's Position in Industry Market Structure
Market-capitalization share and concentration across all 18 companies in Aspira Women S Health Inc's industry classification, broader than the peer set above. Market cap in millions of $.Aspira Women S Health Inc ranks #13 of 18 companies by market capitalization in its industry, holding 0.01 % of total industry market cap. The industry's Herfindahl-Hirschman Index (HHI) is 5,904, indicating a highly concentrated market structure (see Methodology: Market Structure & Concentration).
| Rank | Company | Market Cap | Industry Share |
|---|---|---|---|
| 1 | Idexx Laboratories Inc | 53,195 | 76.00 % |
| 2 | Lantheus Holdings Inc | 6,799 | 9.71 % |
| 3 | Neogen Corporation | 2,540 | 3.63 % |
| 4 | Celldex Therapeutics inc | 2,201 | 3.14 % |
| 5 | Intellia Therapeutics Inc | 1,234 | 5.2% |
| 6 | Trinity Biotech Plc | 1,234 | 5.2% |
| 7 | Quidelortho Corp | 1,234 | 5.2% |
| 8 | Myriad Genetics Inc | 1,234 | 5.2% |
| 9 | Achieve Life Sciences Inc | 1,234 | 5.2% |
| 10 | Alpha Teknova Inc | 1,234 | 5.2% |
| 13 | Aspira Women s Health inc | 7 | 0.01 % |
Market cap and industry share for the rest of Aspira Women S Health Inc's industry peers requires a Commercial License.
Source: CSIMarket API (daily market-structure computation) across CSIMarket's industry classification, market capitalization as of 2026-11-05.
Aspira Women S Health Inc's Same-Size Peers & Stock Performance
Peers chosen by closeness in market-cap rank within the same industry classification (not the named-competitor list above). Trailing 12-month total return, 3-month price momentum, beta and Sharpe ratio vs the broad U.S. market.| Rank | Company | Market Cap | TTM Return |
|---|---|---|---|
| 8 | Myriad Genetics Inc | 596 | -1.16 % |
| 9 | Achieve Life Sciences Inc | 596 | 37.84 % |
| 10 | Alpha Teknova Inc | 423 | 53.47 % |
| 11 | Immucell Corporation | 91 | 73.25 % |
| 12 | Insight Molecular Diagnostics Inc | 1,234 | 12.3% |
| 13 | Aspira Women s Health inc | 7 | - |
| 14 | Cardio Diagnostics Holdings Inc | 1,234 | 12.3% |
| 15 | Biomerica Inc | 1,234 | 12.3% |
| 16 | Qc Technologies Inc | 1,234 | 12.3% |
| 17 | Volitionrx Limited | 1,234 | 12.3% |
| 18 | Burzynski Research Institute Inc | 1,234 | 12.3% |
Market cap, return, momentum, beta and Sharpe ratio for the rest of Aspira Women S Health Inc's same-size peers requires a Commercial License.
Source: CSIMarket API (daily market-structure computation); returns and risk metrics as of 2026-11-05. Beta and Sharpe ratio are versus the broad U.S. equity market, not this industry.
Aspira Women S Health Inc's Profitability & Cost Structure
Trailing 12-month margins from SEC-filed financials. Operating margin is compared to the In Vitro & In Vivo Diagnostic Substances industry median; gross margin, EBITDA margin and capital intensity are compared to the live industry average (22 companies). See the full In Vitro & In Vivo Diagnostic Substances industry profitability benchmarks.| Metric | Company | Industry | Difference |
|---|---|---|---|
| Gross Margin | 43.11 % | 24.05 % (avg) | +19.1 pp |
| Operating Margin | -76.43 % | industry median | -76.3 pp |
| EBITDA Margin | -82.70 % | -12.53 % (avg) | -70.2 pp |
| Capital Intensity (Capex / Revenue) | 6.10 % | 4.16 % (avg) | +1.9 pp |
Source: CSIMarket API, trailing 12 months. SG&A and R&D as a share of revenue have limited coverage as this data is backfilled and appear only where reported. Higher capital intensity is not inherently negative; it reflects the industry's asset requirements.
Aspira Women S Health Inc's Valuation vs Competitive Position
Valuation multiples vs the In Vitro & In Vivo Diagnostic Substances industry average (22 companies, excluding loss-making/negative-equity outliers), alongside returns on capital for context on whether a premium or discount lines up with measurably stronger or weaker returns. See the full In Vitro & In Vivo Diagnostic Substances industry valuation benchmarks.| Metric | Company | Industry Average | Difference |
|---|---|---|---|
| P/E | - | 62.0x | - |
| EV / EBITDA | - | 16.4x | - |
| P/B | -3.0x | 4.1x | -7.0x |
| Return on Equity | - | industry aggregate | - |
| Return on Invested Capital | - | -6.26 % (avg) | - |
Source: CSIMarket API, trailing 12 months. A valuation premium or discount is not, by itself, a judgment of over- or under-valuation. Compare it against the return and growth context shown elsewhere on this page.
Aspira Women S Health Inc's Multi-Year Financial Trajectory
Fiscal-year revenue growth, operating margin, return on invested capital and P/E, as reported in company reports.| Metric | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue Growth | -2.18 % | 48.64 % | -103.91 % | - | 20.14 % | 11.85 % | -7.37 % | 5.14 % |
| Operating Margin | -371.21 % | -336.67 % | 1,369.24 % | -478.49 % | -380.47 % | - | - | -88.76 % |
| Return on Invested Capital | -68.90 % | -76.46 % | -31.62 % | -37.37 % | -99.82 % | -692.59 % | - | - |
| P/E | - | - | - | - | - | - | - | - |
Source: CSIMarket API, fiscal-year figures. P/E is this company's own historical ratio at each fiscal year end and can swing sharply around an earnings trough: that is real, not a data error.
Aspira Women S Health Inc's BCG Growth-Share Matrix
See Methodology: BCG Growth-Share Matrix for how relative share and growth are calculated and thresholded.
Aspira Women S Health Inc falls in the Dog quadrant: relative market share of 0.00x vs its largest competitor, in an industry growing revenue -1.8% (median, trailing 12 months).
Source: CSIMarket API (market-cap share and industry revenue growth). The 10% growth and 1.0x share lines are standard textbook thresholds, not derived from this industry's own distribution. A caveat worth reading alongside this chart: Idexx Laboratories Inc alone holds 76% of this industry's market cap. In an industry this dominated by one leader, the framework will place nearly every OTHER company in "Dog" or "Question Mark" purely because relative share is measured against that leader, regardless of how strong those other companies actually are on their own fundamentals. Check the Profitability, Valuation and Financial Strength sections above before treating this quadrant label as a verdict.
Aspira Women S Health Inc's Competitive Forces (Porter's Five Forces)
Only the forces this data can support honestly are shown; the other three are marked as such rather than guessed.| Force | Assessment | Basis |
|---|---|---|
| Competitive Rivalry | Low | Industry HHI of 5,904 (see Industry Market Structure & Concentration above) |
| Barriers to Entry | High (capital intensive) | Capital intensity (capex / revenue) of 6.10 % vs industry average 4.16 % (see Profitability & Cost Structure above) |
Note: see Methodology: Porter's Five Forces. Supplier power and buyer power are covered on Aspira Women S Health Inc's dedicated Suppliers and Customers pages, not here.
Aspira Women S Health Inc's Industry Attractiveness & Competitive Strength
See Methodology: GE/McKinsey Matrix for how the two axes are built.
Aspira Women S Health Inc falls in the Medium attractiveness / Low strength cell: Harvest.
Source: CSIMarket API, trailing 12 months. Each axis score is a simple 1(low)/2(medium)/3(high) average across its three inputs -- a transparent, disclosed simplification, not a validated academic scoring model.
Aspira Women S Health Inc's SWOT
Every point below is a fixed rule applied to a metric already shown elsewhere on this page (Market Structure, Profitability, Valuation, Run-Rate, Stock Performance, Quality Breadth) not an independent strategic assessment. A blank quadrant means no rule was met, not that none apply.Strengths
No rule matched.
Weaknesses
- Operating margin 76.3 points below the industry median.
- Latest-quarter revenue run-rate is decelerating (-99.2% annualized vs trailing 12 months).
- Low relative market share vs the industry leader (0.00x).
- Piotroski F-Score of 2 or below, the standard financial-distress signal.
Opportunities
No rule matched.
Threats
- Industry dominated by Idexx Laboratories Inc, holding 76.00 % of industry market cap.
- High capital intensity requires continuous reinvestment just to keep pace with the industry.
Methodology: see Methodology: SWOT Analysis.
Aspira Women S Health Inc's Financial Strength vs Peers Comparison
Quick ratio, working capital, debt to equity and asset turnover, trailing 12 months| Company | Quick Ratio | Working Capital | Debt / Equity |
|---|---|---|---|
| Aspira Women s Health inc | 0.40 | 0.89 | - |
| Progressive Corp | 0.06 | 1.06 | 0.24 |
| Marsh and Mclennan Companies Inc | 0.52 | 1.13 | 1.36 |
| Travelers Companies inc | 0.01 | 1.08 | 0.29 |
| The Cigna Group | 0.12 | 0.82 | 0.76 |
| Aon Plc | 0.06 | 1.06 | 1.86 |
Sign in to see all peers for Aspira Women s Health inc .
Quick ratio = cash / current liabilities; working capital ratio = current assets / current liabilities; asset turnover = revenue / total assets. Peers in the Blank Checks industry are excluded.
Aspira Women S Health Inc's Revenue and Income Growth vs Peers
Quarterly revenue and net income growth, year over year and quarter over quarter| Company | Period | Revenue Y/Y | Income Y/Y |
|---|---|---|---|
| Aspira Women s Health inc | Q2 2026 | -99.0 % | - |
| Progressive Corp | Q3 2026 | +3.0 % | -2.8 % |
| Marsh and Mclennan Companies Inc | Q3 2026 | +7.9 % | +6.7 % |
| Travelers Companies inc | Q3 2026 | -0.5 % | +1.5 % |
| The Cigna Group | Q2 2026 | +6.7 % | +22.4 % |
| Aon Plc | Q3 2026 | +2.6 % | +1.3 % |
| PEERS TOTAL | +5.8 % | +30.9 % |
Sign in to see all peers for Aspira Women s Health inc .
Growth is shown only where both periods are positive. Peers in the Blank Checks industry are excluded.
Aspira Women S Health Inc's Peers' Costs of Sales and Capital Expenditures
Context for revenue growth: peer costs and capex, year over year and quarter over quarter| Company | Period | Costs Y/Y | Capex Y/Y |
|---|---|---|---|
| Aspira Women s Health inc | Q2 2026 | - | - |
| Progressive Corp | Q3 2026 | +1,016.0 % | +75.8 % |
| Marsh and Mclennan Companies Inc | Q3 2026 | - | +12.5 % |
| Travelers Companies inc | Q3 2026 | +0.4 % | - |
| The Cigna Group | Q2 2026 | +6.4 % | - |
| Aon Plc | Q3 2026 | - | +36.2 % |
Sign in to see all peers for Aspira Women s Health inc .
Aspira Women S Health Inc's Returns and Turnover vs Peers
ROA, ROI and ROE (trailing 12 months), receivables and inventory turnover| Company | ROA | ROI | ROE |
|---|---|---|---|
| Aspira Women s Health inc | - | - | - |
| Progressive Corp | 9.34% | 10.98% | 35.44% |
| Marsh and Mclennan Companies Inc | 6.96% | 11.21% | 27.25% |
| Travelers Companies inc | 5.82% | 8.95% | 26.20% |
| The Cigna Group | 4.44% | 6.84% | 16.41% |
| Aon Plc | 7.15% | 9.96% | 40.15% |
Sign in to see all peers for Aspira Women s Health inc .
ROA = net income / total assets; ROI = net income / investments; ROE = net income / equity; turnover ratios use trailing 12 month revenue (receivables) and cost of sales (inventory).
Aspira Women S Health Inc's Valuation vs Peers
P/E, price to sales, PEG, price to cash flow and price to book| Company | P/E | Price / Sales |
|---|---|---|
| Aspira Women s Health inc | - | 0.76 |
| Progressive Corp | 11.74 | 1.48 |
| Marsh and Mclennan Companies Inc | 25.17 | 3.52 |
| Travelers Companies inc | 10.61 | 1.73 |
| The Cigna Group | 12.79 | 0.28 |
| Aon Plc | 19.08 | 4.14 |
| PEERS AVERAGE | 6.22 | 0.85 |
Sign in to see all peers for Aspira Women s Health inc .
P/E = price / diluted EPS (trailing 12 months); PEG = P/E divided by EPS growth; the average row divides the peers' combined market cap by their combined income, sales, cash flow and equity.